Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

[1]  J. Foekens,et al.  A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds , 2015, PloS one.

[2]  G. Brandi,et al.  Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST) , 2015, BMC Genomics.

[3]  Charlotte Soneson,et al.  A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome , 2015, Clinical Cancer Research.

[4]  Marc Peeters,et al.  New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? , 2015, Oncotarget.

[5]  Alan Sharpe,et al.  High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma. , 2015, Cancer research.

[6]  J Carl Barrett,et al.  Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System , 2014, Clinical Cancer Research.

[7]  Justin Guinney,et al.  Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients , 2013, Clinical Cancer Research.

[8]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[9]  G. Troncone,et al.  KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond , 2013, Journal of Clinical Pathology.

[10]  A. Berchuck,et al.  Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. , 2013, Gynecologic oncology.

[11]  S. Knuutila,et al.  MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. , 2012, Cancer genetics.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[13]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[14]  C. Lebbé,et al.  A Reliable Method for the Selection of Exploitable Melanoma Archival Paraffin Embedded Tissues for Transcript Biomarker Profiling , 2012, PloS one.

[15]  David Fenstermacher,et al.  Implementing personalized medicine in a cancer center. , 2011, Cancer journal.

[16]  Peter C. Hollenhorst,et al.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. , 2011, Genes & development.

[17]  L. Waldron,et al.  mRNA transcript quantification in archival samples using multiplexed, color-coded probes , 2011, BMC biotechnology.

[18]  Lorenza Mittempergher,et al.  Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue Are Largely Comparable to Fresh Frozen Matched Tissue , 2011, PloS one.

[19]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[20]  C. Paweletz,et al.  A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors , 2010, BMC Medical Genomics.

[21]  E. Espinosa,et al.  Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. , 2010, BioTechniques.

[22]  B. Taylor,et al.  Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). , 2010, Cancer research.

[23]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[24]  J. Reid,et al.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Fontanini,et al.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.

[26]  Timothy J. Yeatman,et al.  Predictive biomarkers: identification and verification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Ann M. Hess,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Filtering for increased power for microarray data analysis , 2008 .

[28]  Richard D. Kennedy,et al.  RNA expression analysis from formalin fixed paraffin embedded tissues , 2008, Histochemistry and Cell Biology.

[29]  Y. Ward,et al.  TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation , 2008, BMC Cancer.

[30]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[31]  Silke von Ahlfen,et al.  Determinants of RNA Quality from FFPE Samples , 2007, PloS one.

[32]  Daryl A. Scott,et al.  Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development , 2007, Development.

[33]  Yingdong Zhao,et al.  Analysis of Gene Expression Data Using BRB-Array Tools , 2007, Cancer informatics.

[34]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[35]  E. Wit.  Design and Analysis of DNA Microarray Investigations , 2004, Human Genomics.

[36]  S. Dower,et al.  Human Tribbles, a Protein Family Controlling Mitogen-activated Protein Kinase Cascades* , 2004, Journal of Biological Chemistry.

[37]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[38]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Hilsenbeck,et al.  Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. , 1999, Journal of the National Cancer Institute.

[40]  H. Reesink,et al.  The duration of fixation influences the yield of HCV cDNA-PCR products from formalin-fixed, paraffin-embedded liver tissue. , 1994, Journal of virological methods.

[41]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[42]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[43]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[44]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.